Skip to main content

Advertisement

Table 5 Results of a scenario analysis

From: Economic evaluation of pneumococcal conjugate vaccination in The Gambia

No. Selected alternative scenarios ICER (US$ per DALYa averted)
   PCV7 PCV9 &10 PCV13
1 Immunity waning (no waning up to age 5, 25% decrease up to age 15, and 50% decrease up to age 30)
Serotype replacement (by 25%)
No herd immunity
4,110 1,220 1,010
2 No Immunity waning
Serotype replacement (by 25%)
No herd immunity
3,960 1,170 970
3 No Immunity waning
Serotype replacement (increased incidence of non-primary endpoint pneumonia among vaccinated)
No herd immunity
900 650 550
4 No Immunity waning
No serotype replacement
No herd immunity
670 490 410
5 No Immunity waning
Serotype replacement (increased incidence of non-primary endpoint pneumonia among vaccinated)
Herd immunity (assumed incidence decrease by 32%, 32%, 8%, and 18% for individuals aged 5-19 years, 20-39 years, 40-64 years, and 65 years and older)
830 550 480
6 No Immunity waning
No serotype replacement
Herd immunity (assumed incidence decrease by 32%, 32%, 8%, and 18% for individuals aged 5-19 years, 20-39 years, 40-64 years, and 65 years and older)
630 430 370
  1. DALY: disability-adjusted life year, ICER: incremental cost-effectiveness ratio.
  2. a DALYs calculated without age-weighting (K = 0).